Impact of the severity of Alzheimer's disease on the quality of life, activities of daily living, and caregiving costs for institutionalized patients on anti-Alzheimer medications in Japan

Manuscript Number: 

20-1514R1

Author(s): 
Takumi Ashizawa, Mie Azuma, Kenichi Fujimoto, Ataru Igarashi, Shunya Ikeda, Tsukasa Kobayashi, Yukinori Sakata, Yoshimasa Takase

Disclosures

Takumi Ashizawa

  • Nothing to Disclose

Mie Azuma

  • Sponsors:
    Eisai Co.,Ltd.

Kenichi Fujimoto

  • Sponsors:
    Eisai Co.,Ltd.

Ataru Igarashi

  • Consulting Fees:
    Eisai Co.,Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co, Ltd., Takeda Pharmaceutical Co. Ltd, Janssen Pharmaceutical K.K., Celgene Corporation, Shionogi & Co. Ltd.

Shunya Ikeda

  • Consulting Fees:
    Eisai Co.,Ltd.

Tsukasa Kobayashi

  • Nothing to Disclose

Yukinori Sakata

  • Sponsors:
    Eisai Co.,Ltd.

Yoshimasa Takase

  • Consulting Fees:
    Nichi-Iko Pharmaceutical Co., Ltd., Syakai-Hoken-Syuppan-Sya Co., Ltd., Benesse Senior Support Co ., Ltd.
    Lecture Fees:
    IQVIA Inc., Eisai Co., Ltd., Mylan EPD, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Espha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Celgene Corporation, Novartis Pharma K.K., Shionogi & Co., Ltd.. Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd.,